October 18, 2007
28:1332 Diversity-Product Liability
News Coverage, Answers, Appeals, Complaints, Motions, Orders, Trial Notes
A Pennsylvania federal judge on Tuesday denied GlaxoSmithKline PLC's bid to partially dismiss false advertising claims brought by Santa Clara County, Calif., over GSK's diabetes medication Avandia, rejecting its argument that the claims must be based on false advertising displayed within the county.
GlaxoSmithKline LLC failed Wednesday to escape a trio of racketeering class actions in Pennsylvania federal court alleging its concealment of heart risks associated with the diabetes drug Avandia conned health benefit payors into covering pricey prescriptions.
Plaintiffs' attorneys on Thursday filed a plan in Pennsylvania federal court to split $143 million to resolve a fee dispute in what could be a $2.3 billion settlement in a massive multidistrict litigation over GlaxoSmithKline PLC's alleged failure to warn consumers about health risks related to its diabetes drug Avandia.
A group of plaintiffs urged a Pennsylvania federal judge on Thursday to endorse the transfer of their suits claiming the GlaxoSmithKline PLC diabetes drug Avandia caused heart attacks from multidistrict litigation to the courts where they were filed, arguing the MDL had run its course.
A group of 239 plaintiffs in multidistrict litigation for heart disease claims against GlaxoSmithKline PLC over diabetes drug Avandia asked a Pennsylvania federal judge to disburse the remaining funds from their settlement agreement, saying the pharma giant refuses to release the money.
A federal judge on Wednesday sent two cases back to state court from a multidistrict litigation against GlaxoSmithKline PLC for alleged Medicaid fraud related to its diabetes drug Avandia, saying there weren't enough significant federal issues to justify keeping the cases in federal court.
GlaxoSmithKline PLC has settled a majority of state cases and multidistrict litigation cases over its alleged failure to warn consumers about health risks related to diabetes drug Avandia, which has been linked to increased occurrences of heart attack and stroke, the company said Tuesday.
Less than a week after GlaxoSmithKline PLC paid $3 billion to settle U.S. government probes into, among other practices, its marketing of Avandia, a Pennsylvania federal judge on Monday pushed the drugmaker toward mediation with plaintiffs in multidistrict litigation over the controversial diabetes drug.
A Pennsylvania federal judge ruled Wednesday that a California county can't personally pursue a false advertising suit in multidistrict litigation over GlaxoSmithKline PLC's alleged concealment of the risks of diabetes medication Avandia, but that it can assert the claims on behalf of state residents.
GlaxoSmithKline PLC has lost its bid to block three doctors from testifying about the alleged health risks of Avandia in a multidistrict litigation alleging the company concealed the diabetes medication's potential to cause heart attack and stroke in some patients.